MoonLake plunged as much as 87% in US premarket trading, with the stock set to erase most of its $4 billion capitalization. The key data point for MoonLake’s sonelokimab in patients with moderate to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback